Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
09/2000
09/27/2000CN1268112A Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives
09/27/2000CN1268027A Chemical and pharmacological standardization of herbal extracts
09/27/2000CN1267548A Sleep regulating composition prepared with melatonin and diazepam
09/27/2000CN1267527A Pain-relieving arthralgia dredging Chinese medicine preparation
09/27/2000CN1267523A Chinese medicine composition for treating intractable headache
09/27/2000CN1056846C Spiro-azabicyclic compounds useful in therapy
09/27/2000CN1056837C 5-arylisoxazol-4-yl-substituted 2-aminocarboxylic acid compound, its medical composition and use
09/27/2000CN1056765C Tranquillizer composition for treating chronic nervous disease
09/27/2000CN1056762C Brain-refreshing analgesic powder medicine
09/26/2000US6124463 Treatment of affective disorder, anxiety or depression
09/26/2000US6124456 Adenosine antagonists
09/26/2000US6124338 Treating migraine headache
09/26/2000US6124328 Methods and compositions for stimulating neurite growth
09/26/2000US6124325 Triazole antifungal agents
09/26/2000US6124321 An enzyme inhibitor for enhancing memory or treating or preventing alzheimer's disease
09/26/2000US6124318 A neurotrophic drug treating or preventing a disease involving neuronal degeneration such as senile dementia of the alzheimer type
09/26/2000US6124316 Compounds which are specific antagonists of the human NK3 receptor and their use as medicinal products and diagnostic tools
09/26/2000US6124312 Heterocyclic compounds
09/26/2000US6124308 Optically active phenyl pyrimidine derivatives as analgesic agent
09/26/2000US6124300 Treating anxiety or depression
09/26/2000US6124296 Arylglycinamide derivatives, methods of producing these substances and pharmaceutical compositions containing such compounds
09/26/2000US6124294 Compounds having high affinity for dopamine d3 receptor; used to treat disorders which respond to dopamine d3 ligands
09/26/2000US6124288 Phosphodiesterase iv inhibitors
09/26/2000US6124285 Indole-2,3-dione-3-oxime derivatives
09/26/2000US6124283 Substituted 1,2,3,4-tetrahydronaphthalene derivatives
09/26/2000US6124281 Azolobenzazepine derivatives as neurologically active agents
09/26/2000US6124278 Acylbenzoxazines for enhancing synaptic response
09/26/2000US6123916 For treating disorders with an aetiology comprising or associated with excess of gh-secretion
09/26/2000CA2190011C Method for reduction of headache pain
09/26/2000CA2024572C N-substituted-4-pyrimidinamines and-pyrimidinediamines, a process for their preparation and their use as medicaments
09/21/2000WO2000055620A1 Non-mammalian transgenic animal having an adult onset neurodegenerative phenotype
09/21/2000WO2000055371A1 27 human secreted proteins
09/21/2000WO2000055352A2 50 human secreted proteins
09/21/2000WO2000055351A1 Human colon cancer associated gene sequences and polypeptides
09/21/2000WO2000055350A1 Human cancer associated gene sequences and polypeptides
09/21/2000WO2000055343A2 Retrovirus producting cells utilizing a high multiplicity of transduction
09/21/2000WO2000055332A2 Human regulators of intracellular phosphorylation
09/21/2000WO2000055323A1 Differential expression of organellar gene products
09/21/2000WO2000055321A2 Vertebrate protein slit, dna sequence encoding it and uses thereof
09/21/2000WO2000055320A1 Human pancreas and pancreatic cancer associated gene sequences and polypeptides
09/21/2000WO2000055318A2 Abc1 polypeptide and methods and reagents for modulating cholesterol levels
09/21/2000WO2000055306A1 Cells, cell populations, and methods of making and using same
09/21/2000WO2000055201A1 49 human secreted proteins
09/21/2000WO2000055200A1 50 human secreted proteins
09/21/2000WO2000055199A1 47 human secreted proteins
09/21/2000WO2000055195A1 Compositions for promoting nerve regeneration
09/21/2000WO2000055180A2 Human lung cancer associated gene sequences and polypeptides
09/21/2000WO2000055174A1 Human prostate cancer associated gene sequences and polypeptides
09/21/2000WO2000055173A1 Human breast and ovarian cancer associated gene sequences and polypeptides
09/21/2000WO2000055171A1 50 human secreted proteins
09/21/2000WO2000055161A1 6-substituted biaryl purine derivatives as potent cyclin/cdk inhibitors and antiproliferative agents
09/21/2000WO2000055159A2 Substituted aza-oxindole derivatives
09/21/2000WO2000055155A2 Heterocyclic compounds as adenosine deaminase inhibitors
09/21/2000WO2000055154A1 Modified amino-acid amides as cgrp antagonists
09/21/2000WO2000055153A1 Amide derivatives
09/21/2000WO2000055152A1 Aromatic heterocyclic compounds as anti-inflammatory agents
09/21/2000WO2000055139A2 Heterocyclic urea and related compounds useful as anti-inflammatory agents
09/21/2000WO2000055137A1 Compounds and methods for modulation of estrogen receptors
09/21/2000WO2000055133A1 1-acyl-7-nitroindoline derivatives, their preparation and their use as photocleavable precursors
09/21/2000WO2000055127A1 Gamma-ketoacid dipeptides as inhibitors of caspase-3
09/21/2000WO2000055126A2 N-cyanomethylamides as protease inhibitors
09/21/2000WO2000055125A2 N-cyanomethyl amides as protease inhibitors
09/21/2000WO2000055120A1 Amide derivatives
09/21/2000WO2000055114A1 Substituted 2-aminobenzamide caspase inhibitors and the use thereof
09/21/2000WO2000055072A2 Aerosol metering valve
09/21/2000WO2000054815A2 Expression of dna or proteins in c. elegans
09/21/2000WO2000054806A1 Insulin-like growth factor binding protein-4 protease
09/21/2000WO2000054804A1 Use of tgf-beta inhibitors for treating cerebral disorders
09/21/2000WO2000054802A2 Method of expressing antigens on the surface of antigen presenting cells by photochemical internalization
09/21/2000WO2000054794A1 Wafer delivery system
09/21/2000WO2000054791A1 Use of extracts from ginkgo biloba leaves for treating sleep disorders
09/21/2000WO2000054772A1 Amyotropic lateral sclerosis treatment with a combination of riluzole and an ampa receptor antagonist
09/21/2000WO2000054766A1 Agents and methods for promoting production gains in animals
09/21/2000WO2000054765A1 Method of treating eating disorders
09/21/2000WO2000054764A2 A method of treating bulimia nervosa and related eating disorders by administration of atypical antipsychotic medications
09/21/2000WO2000054763A2 Pharmaceutical compositions comprising polymorphic forms of dehydroepiandrosterone
09/21/2000WO2000054759A2 Lxr modulators
09/21/2000WO2000054756A2 Nitrate esters and their use for introducing neuroprotection and cognition enhancement
09/21/2000WO2000054754A2 Composition comprising isoquercetin and ascorbic acid in a sustained release form
09/21/2000WO2000054745A2 Devices and methods for pain management
09/21/2000WO2000040716A3 Soluble receptor br43x2 and methods of using them for therapy
09/21/2000WO2000040225A3 Inhibition of tnf activity
09/21/2000WO2000039077A3 Thyroid receptor ligands
09/21/2000WO2000038785A3 Methods for treating certain diseases using naaladase inhibitors
09/21/2000WO2000026227A9 Ldl related protein and uses thereof
09/21/2000WO2000010551A3 Methods of using and compositions comprising dopamine reuptake inhibitors
09/21/2000WO2000001668A3 Naaladase inhibitors useful as pharmaceutical compounds and compositions
09/21/2000DE19911371A1 Arzneimittel zur Behandlung von funktionellen Störungen und Erkrankungen der unteren Darmwege, insbesondere von damit einhergehenden abdominalen visceralen Schmerzen Drugs for the treatment of functional disorders and diseases of the lower intestinal tracts, especially of associated abdominal visceral pain
09/21/2000DE19910986A1 Verwendung von Xenon bei der Behandlung von Neurointoxikationen Use of xenon in the treatment of Neurointoxikationen
09/21/2000DE19910108A1 Zellen, die ein Amyloidvorläuferprotein und eine alpha-Sekretase coexprimieren, ein Testverfahren zur Identifikation alpha-Sekretase-aktiver Substanzen sowie eines zur Identifikation weiterer Sekretasen, ein Testverfahren zur Bestimmung der Anfälligkeit gegenüber Morbus Alzheimer und Verwendung von Nukleinsäuren, die für eine alpha-Sekretase codieren, für die Gentherapie Cells, which co-express an amyloid precursor protein and an alpha-secretase, a test method for identifying alpha-secretase active substances as well as one further for identifying secretases, a test method for determining the susceptibility to Alzheimer's disease, and use of nucleic acids encoding an alpha-secretase , for gene therapy
09/21/2000CA2368150A1 1-acyl-7-nitroindoline derivatives, their preparation and their use as photocleavable precursors
09/21/2000CA2368148A1 Novel compounds and compositions as protease inhibitors
09/21/2000CA2368122A1 Novel compounds and compositions as protease inhibitors
09/21/2000CA2368068A1 27 human secreted proteins
09/21/2000CA2367895A1 Compounds and methods for modulation of estrogen receptors
09/21/2000CA2367862A1 Gamma-ketoacid dipeptides as inhibitors of caspase-3
09/21/2000CA2367595A1 Lxr modulators
09/21/2000CA2367444A1 Agents and methods for promoting production gains in animals
09/21/2000CA2367409A1 Metering valve
09/21/2000CA2367357A1 Method
1 ... 1484 1485 1486 1487 1488 1489 1490 1491 1492 1493 1494 1495 1496 1497 1498 1499 1500 1501 1502 1503 1504 ... 1833